company background image
GNRO

GeNeuro ENXTPA:GNRO Stock Report

Last Price

€2.19

Market Cap

€54.5m

7D

0%

1Y

-46.1%

Updated

08 Aug, 2022

Data

Company Financials +
GNRO fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health3/6
Dividends0/6

GNRO Stock Overview

GeNeuro SA, a clinical-stage biopharmaceutical company, develops drugs for the treatment of neurodegenerative and autoimmune diseases.

GeNeuro Competitors

Price History & Performance

Summary of all time highs, changes and price drops for GeNeuro
Historical stock prices
Current Share Price€2.19
52 Week High€4.24
52 Week Low€2.07
Beta0.65
1 Month Change-5.20%
3 Month Change-28.66%
1 Year Change-46.06%
3 Year Change-37.43%
5 Year Change-80.92%
Change since IPO-82.09%

Recent News & Updates

Shareholder Returns

GNROFR BiotechsFR Market
7D0%2.0%0.2%
1Y-46.1%-41.0%-6.7%

Return vs Industry: GNRO underperformed the French Biotechs industry which returned -41% over the past year.

Return vs Market: GNRO underperformed the French Market which returned -6.7% over the past year.

Price Volatility

Is GNRO's price volatile compared to industry and market?
GNRO volatility
GNRO Average Weekly Movement6.9%
Biotechs Industry Average Movement6.6%
Market Average Movement5.0%
10% most volatile stocks in FR Market9.0%
10% least volatile stocks in FR Market2.9%

Stable Share Price: GNRO is more volatile than 75% of French stocks over the past 3 months, typically moving +/- 7% a week.

Volatility Over Time: GNRO's weekly volatility (7%) has been stable over the past year, but is still higher than 75% of French stocks.

About the Company

FoundedEmployeesCEOWebsite
200617Jesus Martin-Garciahttps://www.geneuro.com

GeNeuro SA, a clinical-stage biopharmaceutical company, develops drugs for the treatment of neurodegenerative and autoimmune diseases. The company’s lead therapeutic candidate is temelimab, a monoclonal antibody, which has completed Phase IIb clinical trial for multiple sclerosis; and is in Phase IIa to treat type 1 diabetes, as well as is in Phase I for the treatment of chronic inflammatory demyelinating polyneuropathy. It has cooperative research and development agreements with The National Institute of Neurological Disorders and Stroke to develop novel therapeutic antibodies for the treatment of amyotrophic lateral sclerosis; and Academic labs to develop inflammatory psychosis, as well as a research collaboration agreement with International Center for Infectiology Research; and with Northwestern University for human endogenous retrovirus W envelope protein (HERV-W ENV) in long-haul COVID patients.

GeNeuro Fundamentals Summary

How do GeNeuro's earnings and revenue compare to its market cap?
GNRO fundamental statistics
Market Cap€54.49m
Earnings (TTM)-€6.82m
Revenue (TTM)n/a

0.0x

P/S Ratio

-8.0x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
GNRO income statement (TTM)
Revenue€0
Cost of Revenue€0
Gross Profit€0
Other Expenses€6.82m
Earnings-€6.82m

Last Reported Earnings

Dec 31, 2021

Next Earnings Date

n/a

Earnings per share (EPS)-0.27
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio60.3%

How did GNRO perform over the long term?

See historical performance and comparison
We’ve recently updated our valuation analysis.

Valuation

Is GNRO undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for GNRO?

Other financial metrics that can be useful for relative valuation.

GNRO key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenuen/a
Enterprise Value/EBITDA-8.4x
PEG Ration/a

Price to Book Ratio vs Peers

How does GNRO's PB Ratio compare to its peers?

GNRO PB Ratio vs Peers
The above table shows the PB ratio for GNRO vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPBEstimated GrowthMarket Cap
Peer Average4.6x
ALACT Acticor Biotech SAS
5.5x64.2%€60.9m
ABVX ABIVAX Société Anonyme
4x-18.9%€142.4m
POXEL Poxel
7.6x-12.4%€62.4m
ALONX Onxeo
1.1xn/a€36.8m
GNRO GeNeuro
23.3x-19.6%€54.5m

Price-To-Book vs Peers: GNRO is expensive based on its Price-To-Book Ratio (23.3x) compared to the peer average (4.6x).


Price to Earnings Ratio vs Industry

How does GNRO's PE Ratio compare vs other companies in the FR Biotechs Industry?

Price-To-Book vs Industry: GNRO is expensive based on its Price-To-Book Ratio (23.3x) compared to the French Biotechs industry average (2.5x)


Price to Book Ratio vs Fair Ratio

What is GNRO's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

GNRO PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio23.3x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate GNRO's Price-To-Book Fair Ratio for valuation analysis.


Share Price vs Fair Value

What is the Fair Price of GNRO when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate GNRO's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate GNRO's fair value for valuation analysis.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Target price is more than 20% higher than the current share price, but there are not enough analysts covering the stock to determine statistical confidence in agreement.


Discover undervalued companies

Future Growth

How is GeNeuro forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?

Future Growth Score

0/6

Future Growth Score 0/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


-19.6%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: GNRO is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: GNRO is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: GNRO is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: GNRO is forecast to have no revenue next year.

High Growth Revenue: GNRO is forecast to have no revenue next year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if GNRO's Return on Equity is forecast to be high in 3 years time


Discover growth companies

Past Performance

How has GeNeuro performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


6.9%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: GNRO is currently unprofitable.

Growing Profit Margin: GNRO is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: GNRO is unprofitable, but has reduced losses over the past 5 years at a rate of 6.9% per year.

Accelerating Growth: Unable to compare GNRO's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: GNRO is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-14.2%).


Return on Equity

High ROE: GNRO has a negative Return on Equity (-290.92%), as it is currently unprofitable.


Discover strong past performing companies

Financial Health

How is GeNeuro's financial position?

Financial Health Score

3/6

Financial Health Score 3/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Stable Cash Runway

  • Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: GNRO's short term assets (€4.6M) exceed its short term liabilities (€2.6M).

Long Term Liabilities: GNRO's short term assets (€4.6M) exceed its long term liabilities (€2.5M).


Debt to Equity History and Analysis

Debt Level: GNRO has more cash than its total debt.

Reducing Debt: GNRO's debt to equity ratio has increased from 1% to 60.3% over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: Insufficient data to determine if GNRO has enough cash runway based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if GNRO has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Discover healthy companies

Dividend

What is GeNeuro current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Cash Flow Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate GNRO's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate GNRO's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if GNRO's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if GNRO's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as GNRO has not reported any payouts.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

4.4yrs

Average management tenure


CEO

Jesus Martin-Garcia (60 yo)

6.58yrs

Tenure

€716,068

Compensation

Mr. Jesús Martin-Garcia is the Founding Partner, General Partner, and Director of Eclosion SA. He serves at GeNeuro SA as the Chairman of the Board since February 06, 2006 and Chief Executive Officer since...


CEO Compensation Analysis

Compensation vs Market: Insufficient data to establish whether Jesus's total compensation is reasonable compared to companies of similar size in the French market.

Compensation vs Earnings: Jesus's compensation has been consistent with company performance over the past year.


Leadership Team

Experienced Management: GNRO's management team is considered experienced (4.4 years average tenure).


Board Members

Experienced Board: GNRO's board of directors are considered experienced (7.1 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 12.1%.


Top Shareholders

Company Information

GeNeuro SA's employee growth, exchange listings and data sources


Key Information

  • Name: GeNeuro SA
  • Ticker: GNRO
  • Exchange: ENXTPA
  • Founded: 2006
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: €54.493m
  • Shares outstanding: 24.88m
  • Website: https://www.geneuro.com

Number of Employees


Location

  • GeNeuro SA
  • 3 chemin du PrE-Fleuri
  • Plan-les-Ouates
  • Geneva
  • 1228
  • Switzerland

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/08/08 00:00
End of Day Share Price2022/08/08 00:00
Earnings2021/12/31
Annual Earnings2021/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.